Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.65 |
| ▸ | CTSK | P43235 | 7/20 | 0.65 |
| ▸ | CTSB | P07858 | 2/20 | 0.65 |
| ▸ | CTSL | P07711 | 1/20 | 0.65 |
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | AKT1 | P31749 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 5/20 | 0.55 |
| ▸ | PPARG | P37231 | 4/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27745877 | 0.91 | CTSS (0.62) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL8382083 | 0.88 | CTSS (0.56) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL6592724 | 0.88 | BCL2 (0.62) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL7269746 | 0.87 | CTSS (0.70) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL795685 | 0.87 | ACE (0.79) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL27909397 | 0.87 | ACE (0.79) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL67020 | 0.87 | ACE (0.79) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL606309 | 0.87 | ACE (0.79) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL21473784 | 0.87 | ACE (0.79) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL66220 | 0.87 | ACE (0.79) | CTSSCTSKCTSBCTSLACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158622-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2012-04-17 | — | — | US | disclosed |
| EP-1636224-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LTD (GB) | 2010-07-14 | — | — | EP | disclosed |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-7405210-B2 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | OSI PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | BRADLEY STUART E | 2007-10-18 | — | — | US | disclosed |
| EP-1636224-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | Prosidion Limited (GB) | 2006-03-22 | — | — | EP | disclosed |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| US-6960575-B2 | For use as inhibitors of chymase | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| WO-2004104001-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| US-20040097496-A1 | Novel thiazine derivatives | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-6713472-B1 | 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| EP-1211249-A1 | NOVEL THIAZINE OR PYRAZINE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097496-A1 | Novel thiazine derivatives | CMA1, TPSD1, HRH4 | CTSS 14/4885CTSK 29/4885CTSB 84/4885 |
| US-20070244090-A9 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSPHORYLASE | PYGL, PYGM, PYGB | CTSS 2832/4885CTSK 2977/4885CTSB 2518/4885 |
| US-20090023703-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | CTSS 2832/4885CTSK 2977/4885CTSB 2518/4885 |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | CTSS 2832/4885CTSK 2977/4885CTSB 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.